The Role of Inflammatory Parameters and Antibody Seroconversion on COVID-19 Outcomes in Patients with Central Obesity
Background: Central obesity increases the risk of developing poor outcomes of COVID-19. The pro-inflammatory state and antibody dysfunction are thought to contribute to poor outcomes; however, the evidence is unclear. Methods: This is a cohort study among COVID-19 patients with central obesity in Dr...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2024-10-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | https://actamedindones.org/index.php/ijim/article/view/2791 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585134916763648 |
|---|---|
| author | Syahidatul Wafa Dicky Levenus Tahapary Evy Yunihastuti Heri Wibowo Cleopas Martin Rumende Kuntjoro Harimurti Ketut Suastika Farid Kurniawan Rona Kartika Tika Pradnjaparamita Dante Saksono Harbuwono |
| author_facet | Syahidatul Wafa Dicky Levenus Tahapary Evy Yunihastuti Heri Wibowo Cleopas Martin Rumende Kuntjoro Harimurti Ketut Suastika Farid Kurniawan Rona Kartika Tika Pradnjaparamita Dante Saksono Harbuwono |
| author_sort | Syahidatul Wafa |
| collection | DOAJ |
| description | Background: Central obesity increases the risk of developing poor outcomes of COVID-19. The pro-inflammatory state and antibody dysfunction are thought to contribute to poor outcomes; however, the evidence is unclear. Methods: This is a cohort study among COVID-19 patients with central obesity in Dr. Cipto Mangunkusumo National General Hospital Jakarta, Indonesia, during the early phase of the COVID-19 pandemic. Our study is a part of the COVID-19, Aging, and Cardiometabolic Risk Factors (CARAMEL) study. From the CARAMEL study, we selected adult non-ICU/HCU inpatient subjects with central obesity that met inclusion/exclusion criteria, collected clinical and anthropometric data, and measured inflammatory cytokines and IgG S-RBD SARS-CoV-2 antibody titers from a stored sample taken at day 2 of hospitalization. The poor clinical outcome of hospitalization was observed. We used the Mann-Whitney test to analyse non-normally distributed data, and T-test for normally-distributed data. The adjusted-relative risk of negative seroconversion antibody for poor outcomes was analysed using logistic regression. Results: 23 of 178 (12.9%) subjects developed poor clinical outcomes during hospitalization. Subjects with poor outcomes had a higher visceral fat area (14.5 vs. 11, p < 0.05), waist circumference and BMI. The level of CRP, pro-inflammatory cytokines (IL-6 and MCP-1) and anti-inflammatory cytokines (IL-1Ra, IL-4, and IL-10) were significantly higher in subjects with poor outcomes, alongside with the lower antibody titer in subjects with poor outcomes. Antibody seroconversion failure increased the risk of developing poor outcomes (aRR 2.696, 95% CI 1.024-7.101), after adjusting for age and sex. Conclusion: In COVID-19 patients with central obesity, we confirmed the association between higher pro- and anti-inflammatory parameters, and lower SARS-CoV-2 antibody with poor outcomes of COVID-19. |
| format | Article |
| id | doaj-art-76fe82c7e1954475a27d8fd160ace34e |
| institution | Kabale University |
| issn | 0125-9326 2338-2732 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | Acta Medica Indonesiana |
| spelling | doaj-art-76fe82c7e1954475a27d8fd160ace34e2025-01-27T04:12:06ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322024-10-01564696The Role of Inflammatory Parameters and Antibody Seroconversion on COVID-19 Outcomes in Patients with Central ObesitySyahidatul Wafa0Dicky Levenus Tahapary1Evy Yunihastuti2Heri Wibowo3Cleopas Martin Rumende4Kuntjoro Harimurti5Ketut Suastika6Farid Kurniawan7Rona Kartika8Tika Pradnjaparamita9Dante Saksono Harbuwono101. Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia. 2. Metabolic Disorder, Cardiovascular and Aging Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.1. Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia. 2. Metabolic Disorder, Cardiovascular and Aging Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia1. Integrated Laboratory, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia. 2. Department of Parasitology, Faculty of Medicine, Universitas Indonesia Hospital, Jakarta, Indonesia.Division of Respirology and Critical Care Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo National General Hospital, Jakarta, IndonesiaDivision of Geriatric, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo National General Hospital, Jakarta, IndonesiaDivision of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Universitas Udayana, Denpasar, Bali, Indonesia1. Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia. 2. Metabolic Disorder, Cardiovascular and Aging Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.Metabolic Disorder, Cardiovascular and Aging Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine Universitas Indonesia, Jakarta, IndonesiaMetabolic Disorder, Cardiovascular and Aging Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia1. Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia. 2. Metabolic Disorder, Cardiovascular and Aging Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.Background: Central obesity increases the risk of developing poor outcomes of COVID-19. The pro-inflammatory state and antibody dysfunction are thought to contribute to poor outcomes; however, the evidence is unclear. Methods: This is a cohort study among COVID-19 patients with central obesity in Dr. Cipto Mangunkusumo National General Hospital Jakarta, Indonesia, during the early phase of the COVID-19 pandemic. Our study is a part of the COVID-19, Aging, and Cardiometabolic Risk Factors (CARAMEL) study. From the CARAMEL study, we selected adult non-ICU/HCU inpatient subjects with central obesity that met inclusion/exclusion criteria, collected clinical and anthropometric data, and measured inflammatory cytokines and IgG S-RBD SARS-CoV-2 antibody titers from a stored sample taken at day 2 of hospitalization. The poor clinical outcome of hospitalization was observed. We used the Mann-Whitney test to analyse non-normally distributed data, and T-test for normally-distributed data. The adjusted-relative risk of negative seroconversion antibody for poor outcomes was analysed using logistic regression. Results: 23 of 178 (12.9%) subjects developed poor clinical outcomes during hospitalization. Subjects with poor outcomes had a higher visceral fat area (14.5 vs. 11, p < 0.05), waist circumference and BMI. The level of CRP, pro-inflammatory cytokines (IL-6 and MCP-1) and anti-inflammatory cytokines (IL-1Ra, IL-4, and IL-10) were significantly higher in subjects with poor outcomes, alongside with the lower antibody titer in subjects with poor outcomes. Antibody seroconversion failure increased the risk of developing poor outcomes (aRR 2.696, 95% CI 1.024-7.101), after adjusting for age and sex. Conclusion: In COVID-19 patients with central obesity, we confirmed the association between higher pro- and anti-inflammatory parameters, and lower SARS-CoV-2 antibody with poor outcomes of COVID-19.https://actamedindones.org/index.php/ijim/article/view/2791inflammatory parametersantibody responsecovid-19 severitycentral obesitypoor outcome |
| spellingShingle | Syahidatul Wafa Dicky Levenus Tahapary Evy Yunihastuti Heri Wibowo Cleopas Martin Rumende Kuntjoro Harimurti Ketut Suastika Farid Kurniawan Rona Kartika Tika Pradnjaparamita Dante Saksono Harbuwono The Role of Inflammatory Parameters and Antibody Seroconversion on COVID-19 Outcomes in Patients with Central Obesity Acta Medica Indonesiana inflammatory parameters antibody response covid-19 severity central obesity poor outcome |
| title | The Role of Inflammatory Parameters and Antibody Seroconversion on COVID-19 Outcomes in Patients with Central Obesity |
| title_full | The Role of Inflammatory Parameters and Antibody Seroconversion on COVID-19 Outcomes in Patients with Central Obesity |
| title_fullStr | The Role of Inflammatory Parameters and Antibody Seroconversion on COVID-19 Outcomes in Patients with Central Obesity |
| title_full_unstemmed | The Role of Inflammatory Parameters and Antibody Seroconversion on COVID-19 Outcomes in Patients with Central Obesity |
| title_short | The Role of Inflammatory Parameters and Antibody Seroconversion on COVID-19 Outcomes in Patients with Central Obesity |
| title_sort | role of inflammatory parameters and antibody seroconversion on covid 19 outcomes in patients with central obesity |
| topic | inflammatory parameters antibody response covid-19 severity central obesity poor outcome |
| url | https://actamedindones.org/index.php/ijim/article/view/2791 |
| work_keys_str_mv | AT syahidatulwafa theroleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT dickylevenustahapary theroleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT evyyunihastuti theroleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT heriwibowo theroleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT cleopasmartinrumende theroleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT kuntjoroharimurti theroleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT ketutsuastika theroleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT faridkurniawan theroleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT ronakartika theroleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT tikapradnjaparamita theroleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT dantesaksonoharbuwono theroleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT syahidatulwafa roleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT dickylevenustahapary roleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT evyyunihastuti roleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT heriwibowo roleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT cleopasmartinrumende roleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT kuntjoroharimurti roleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT ketutsuastika roleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT faridkurniawan roleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT ronakartika roleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT tikapradnjaparamita roleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity AT dantesaksonoharbuwono roleofinflammatoryparametersandantibodyseroconversiononcovid19outcomesinpatientswithcentralobesity |